Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in ...

After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair ...

Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over. Last reviewed: 26 February 2025 Next review: More evidence on ...

Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults. Last ...

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Last reviewed: 11 December 2024 Next review: More ...

Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line ...

Hybrid closed loop (HCL) systems are recommended as an option for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling ...